Scientists Discover New Human Blood Group MAL

Scientists have identified the genetic cause of the AnWj blood group antigen, a mystery that has persisted since 1972, and have established a new human blood group system named MAL. This breakthrough, detailed in a recent publication, is expected to significantly simplify the process of locating compatible blood donors and recipients for individuals with the extremely rare AnWj-negative blood type. The AnWj antigen's genetic underpinnings were previously unknown, making it challenging to identify individuals who lacked this specific antigen and were therefore at risk of developing antibodies against it during blood transfusions. The discovery of the MAL blood group system provides a clear genetic marker, enabling more precise matching and reducing the likelihood of potentially life-threatening transfusion reactions.

The AnWj antigen is part of a larger collection of antigens found on red blood cells, and variations in these antigens can lead to different blood groups. The International Society of Blood Transfusion (ISBT) recognizes numerous blood group systems, each comprising one or more antigens. The identification of the genetic basis for the AnWj antigen means it will now be classified as a distinct blood group system, the MAL system. This classification is crucial for transfusion medicine, as it allows for standardized identification and communication about blood types globally. Previously, the AnWj antigen was considered an 'unassigned' or 'high-frequency' antigen, meaning it was present in most of the population, making those who lacked it exceptionally rare and difficult to find for transfusion purposes.

Finding AnWj-negative individuals is critical because if they receive blood containing the AnWj antigen, their immune system can produce antibodies against it. This can lead to hemolytic transfusion reactions, where the recipient's body destroys the transfused red blood cells, causing symptoms ranging from fever and chills to severe organ damage and even death. Similarly, if an AnWj-negative person becomes pregnant, their antibodies can cross the placenta and attack the fetus's red blood cells, leading to hemolytic disease of the fetus and newborn (HDFN). The establishment of the MAL blood group system and the understanding of its genetic basis will greatly improve the management of these risks for both transfusion recipients and expectant mothers.

The research involved meticulous genetic analysis and serological testing to pinpoint the specific gene responsible for the AnWj antigen. While the exact gene and its variants are not detailed in the initial reports, the confirmation of a distinct genetic cause solidifies the classification of MAL as a new blood group system. This advancement is a testament to decades of research in blood group genetics and immunology. The implications extend beyond immediate clinical applications, potentially contributing to a deeper understanding of red blood cell biology and the genetic diversity within human populations. The ability to accurately identify and manage rare blood types like AnWj-negative is a significant step forward in transfusion safety and the treatment of conditions requiring blood transfusions or related to blood incompatibilities.